SUMMARY
Patients with diabetes are more prone to developing heart failure in the presence of high blood pressure than those without diabetes. Yes-associated protein (YAP), a key effector of the Hippo signaling pathway, is persistently activated in diabetic hearts, and YAP plays an essential role in mediating the exacerbation of heart failure in response to pressure overload in the hearts of mice fed a high-fat diet. YAP induced dedifferentiation of cardiomyocytes through activation of transcriptional enhancer factor 1 (TEAD1), a transcription factor. Thus, YAP and TEAD1 are promising therapeutic targets for diabetic patients with high blood pressure to prevent the development of heart failure. Activation of the Hippo pathway is intimately involved in the pathogenesis of heart disease, including ischemia/reperfusion injury (6,7), cardiac remodeling, and HF (8, 9) . YAP is also involved in regeneration of the postnatal heart after myocardial infarction (10) (11) (12) .
It has been proposed that either suppression of the The background of all mice was C57BL/6J. Systemic
TEAD1
þ/À mice have been described (13 TRANSVERSE AORTIC CONSTRICTION. The methods used to impose PO in mice have been described (13) .
Male mice at 12 weeks of age were randomly divided into 2 groups: PO with TAC or sham operation. We focused on male mice in this study because previous studies of YAP loss of function in the heart conducted in this laboratory also focused on male mice (13).
Mice were anesthetized with pentobarbital sodium (60 mg/kg) and mechanically ventilated. The number of animals used is described in each figure legend. Immunoblot analyses and histological analyses were conducted as described previously (13). Sample sizes were determined using standard
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YAP Promotes Heart Failure in Diabetes S E P T E M B E R 2 0 1 9 : 6 1 1 -2 2 level of total YAP protein was also increased in the hearts of mice fed HFD ( Figure 1C) . Furthermore, consumption of HFD for 8 weeks significantly downregulated the level of phospho-Lats2, which suggests that this model mimics Hippo deficiency ( Figure 1C, Supplemental Figure 2 ). Echocardiographic measurements (Supplemental Table 3 ) and hemodynamic measurements (Supplemental Table 4 ACTA2, RUNX1, and a-tubulin in the heart (n ¼ 6, each). All results are mean AE SEM. *p < 0.05 by analysis of variance. Abbreviations as in Figure 1 .
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of YAP may correlate with the severity of diabetes (Supplemental Figure 8B) . Ikeda et al. TRANSLATIONAL OUTLOOK 1: YAP and TEAD1 are critically involved in the development of heart failure in the diabetic heart in the presence of high blood pressure.
Although YAP is generally protective against cardiac stress, it can be detrimental under some conditions. Our results clearly show that YAP can be an important therapeutic target in diabetic patients with high blood pressure.
TRANSLATIONAL OUTLOOK 2: Our study suggests that chemical inhibitors of YAP or TEAD1 may be effective in treating patients who have diabetes, high blood pressure, and obesity (metabolic syndrome) to prevent heart failure syndromes.
